Reproductive Medicine Center, Peking University Shenzhen Hospital, Shenzhen, China.
Front Endocrinol (Lausanne). 2021 Oct 11;12:739773. doi: 10.3389/fendo.2021.739773. eCollection 2021.
To compare the effects of early and mid-late follicular phase administration of 150 IU of human chorionic gonadotropin (hCG) on gonadotropin-releasing hormone (GnRH) antagonist protocol in "unpredictable" poor ovarian response (POR) women undergoing fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment.
A retrospective single-center cohort study was conducted on 67 patients with "unpredictable" POR in their first IVF/ICSI cycle receiving GnRH antagonist protocol. Patients were treated with a second IVF/ICSI cycle using the same GnRH antagonist protocol with the same starting dose of recombinant follicle-stimulating hormone (rFSH) as the first cycle; a daily dose of 150 IU of hCG was administrated on either stimulation day 1 (Group A, n = 35) or day 6 (Group B, n = 32). The number of oocytes retrieved, number of usable embryos, serum level of estradiol (E) on day of hCG trigger, and clinical pregnant outcomes were studied.
The addition of 150 IU of hCG on either the first day or sixth day of stimulation increases the serum level of E, luteinizing hormone (LH), and hCG on the day of hCG trigger. Only the use of 150 IU of hCG on the first stimulation day improved the number of oocytes retrieved, mature of oocytes, and usable embryos, but not the addition of hCG on stimulation day 6. Implantation rate, clinical pregnancy rate, and ongoing pregnancy rate showed an increasing trend in patients receiving 150 IU of hCG in the early phase compared with mid-late phase, even thought there was no statistically significant difference.
Our study demonstrated that adding 150 IU of hCG in subsequent GnRH antagonist cycle in "unpredictable" poor responders is associated with the improvement of response to stimulation. Furthermore, early follicular phase addition of 150 IU of hCG significantly increased the number of oocytes retrieved and usable embryos than did the mid-late addition of the same dose.
比较在接受促性腺激素释放激素(GnRH)拮抗剂方案的“不可预测”卵巢反应不良(POR)女性中,早期和中晚期卵泡期给予 150IU 人绒毛膜促性腺激素(hCG)对 GnRH 拮抗剂方案的影响。
对在首次接受 GnRH 拮抗剂方案的体外受精/胞浆内单精子注射(IVF/ICSI)治疗的“不可预测”POR 的 67 例患者进行回顾性单中心队列研究。患者接受相同 GnRH 拮抗剂方案的第二次 IVF/ICSI 周期治疗,起始剂量与第一个周期相同的重组卵泡刺激素(rFSH);在刺激日第 1 天(A 组,n=35)或第 6 天(B 组,n=32)给予 150IU 的 hCG 日剂量。研究了取卵数、可利用胚胎数、hCG 扳机日血清雌二醇(E)水平和临床妊娠结局。
在刺激的第 1 天或第 6 天添加 150IU 的 hCG 均增加了 hCG 扳机日的血清 E、黄体生成素(LH)和 hCG 水平。只有在第 1 次刺激日使用 150IU 的 hCG 改善了取卵数、卵母细胞成熟和可利用胚胎数,但在刺激日第 6 天添加 hCG 则不然。与中晚期添加相比,早期添加 150IU 的 hCG 可提高患者的着床率、临床妊娠率和持续妊娠率,尽管差异无统计学意义。
我们的研究表明,在“不可预测”的 POR 患者中,在后续 GnRH 拮抗剂周期中添加 150IU 的 hCG 与刺激反应的改善有关。此外,与中晚期添加相同剂量的 hCG 相比,早期卵泡期添加 150IU 的 hCG 显著增加了取卵数和可利用胚胎数。